# The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

> **NCT01676116** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 438 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/liraglutide
- **DRUG:** liraglutide
- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT01676116
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-29
- **Primary completion:** 2014-03-11
- **Final completion:** 2014-03-11
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676116, "The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01676116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*